Corsair raises $23M to support testing of treprostinil skin patch
Corsair Pharma has secured $23 million in financing to support clinical testing of a skin patch for the delivery of treprostinil to treat pulmonary arterial hypertension (PAH), the company announced. The transdermal patch is intended to provide continuous and consistent levels of treprostinil, similar to those achieved with…